The preliminary determination by CMS for national US Medicare pricing of KidneyIntelX™ at $950/test is excellent news, and ahead of our assumed $750. Needless to say inclusion on the Clinical Laboratory Fee Schedule, effective from 1st January, represents a strong marker for future market take-up and broad payer acceptance, including not only Medicare but also Medicaid, preferred provider organizations (PPOs) and private payers. On past evidence, the risk of a major setback at the final determin ....
30 Sep 2019
CMS sets price for KidneyIntelX™ at $950, ahead of expectations
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
CMS sets price for KidneyIntelX™ at $950, ahead of expectations
Renalytix Plc (RENX:LON) | 27.5 0 0.0% | Mkt Cap: 34.7m
- Published:
30 Sep 2019 -
Author:
Jens Lindqvist -
Pages:
3
The preliminary determination by CMS for national US Medicare pricing of KidneyIntelX™ at $950/test is excellent news, and ahead of our assumed $750. Needless to say inclusion on the Clinical Laboratory Fee Schedule, effective from 1st January, represents a strong marker for future market take-up and broad payer acceptance, including not only Medicare but also Medicaid, preferred provider organizations (PPOs) and private payers. On past evidence, the risk of a major setback at the final determin ....